Meeting
2012 ASCO Annual Meeting
LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Authors
Carey K. Anders
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Carey K. Anders , Allison Mary Deal , Elizabeth Claire Dees , William Johnson Irvin Jr., Hyman Bernard Muss , Jeanne Noe , Olga Karginova , Barbara Adamo , Aleix Prat , Lisa A. Carey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT01305941
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS656)
DOI
10.1200/jco.2012.30.15_suppl.tps656
Abstract #
TPS656
Poster Bd #
16C
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).
First Author: Carey K. Anders
Poster
2022 ASCO Annual Meeting
Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
First Author: Ian E. Krop
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop
Poster
2013 ASCO Annual Meeting
BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+ HER2- advanced breast cancer.
First Author: Bent Ejlertsen